ClinicalTrials.gov
ClinicalTrials.gov Menu

Immunologic Response to Inactivated Vaccine for Novel H1N1 Virus

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT01023711
Recruitment Status : Completed
First Posted : December 2, 2009
Results First Posted : May 12, 2015
Last Update Posted : May 12, 2015
Sponsor:
Information provided by (Responsible Party):
John Treanor, University of Rochester

December 1, 2009
December 2, 2009
April 24, 2015
May 12, 2015
May 12, 2015
November 2009
November 2010   (Final data collection date for primary outcome measure)
Determination of Immune Response to Vaccination. [ Time Frame: 28 days ]
Number of participants with a 4-fold or greater increase in serum HAI antibody from pre- to 28 day post-vaccination
determination of immune response to vaccination will be the development of the serum antibody assessed by hemagglutination-inhibition (HAI) and neutralization tests [ Time Frame: 28 days ]
Complete list of historical versions of study NCT01023711 on ClinicalTrials.gov Archive Site
Assessment of the Reactogenicity Events Post Vaccination. [ Time Frame: 7 days ]
Number of subjects with reactogenicity events of grade 2 or higher within 7 days of vaccination
assessment of the safety of vaccination will be the rate and severity of solicited adverse events within seven days of vaccine [ Time Frame: 7 days ]
Not Provided
Not Provided
 
Immunologic Response to Inactivated Vaccine for Novel H1N1 Virus
Assessment of the Effect of Age and Priming on the Immunological Response to an Inactivated Vaccine for Novel H1N1 Virus.
The purpose of this study is to describe the immune response to a novel H1N1 influenza vaccination in healthy adults, and to understand the factors that allow healthy adults to respond to a single dose of vaccine even if they have never previously experience novel H1N1 disease or vaccination.
Studies have now determined that only a single dose of inactivated vaccine is needed for immunization against novel H1N1, but the reasons why adults appear to be ready to respond to a single dose are not known.
Interventional
Not Applicable
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Prevention
Influenza
  • Biological: Inactivated H1N1 vaccine
    0.5 ml IM into Deltoid region of arm
    Other Name: Influenza A (H1 N1) 2009 Monovalent Vaccine
  • Biological: Inactivated H1N1 vaccine
    0.5 mL IM X 1 dose
    Other Name: Swine Flu Vaccine
Inactivated H1N1 Vaccine
Subject will recieve 0.5 mL IM injection of Inactivated H1N1 vaccine
Interventions:
  • Biological: Inactivated H1N1 vaccine
  • Biological: Inactivated H1N1 vaccine
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Completed
107
60
July 2011
November 2010   (Final data collection date for primary outcome measure)

Inclusion Criteria:

  • Aged 18-32 years, or 60 years and older
  • No history of Novel H1N1 virus or vaccine
  • Female not able to bear children or not pregnant and agrees to practice effective birth control
  • Female negative pregnancy test
  • Good Health
  • Ability to understand and comply with protocol
  • Provided Informed Consent

Exclusion Criteria:

  • Previous history of vaccination against novel H1N1 or laboratory documented H1N1 infection
  • Previous history of vaccination with A/New Jersey/76 vaccine (for subjects 60 & older
  • History of egg allergy or is allergic to other components of the vaccine
  • Women who are pregnant or breastfeeding or intends to get pregnant during the study period between enrollment & 30 days following vaccination
  • Subject is immunosuppressed as the result of underlying illness or treatment with immunosuppressive or cytotoxic drugs or use of chemotherapy/radiation therapy in the preceding 36 months
  • Subject has active neoplastic disease (excluding non-melanoma skin cancer or prostate cancer that is stable in the absence of therapy) or a history of any hematological malignancy. "Active" is defined as treatment within the past 5 years.
  • Long term (greater than 2 weeks) use of oral or parental steroids, or high- dose inhaled steroids (>800 mcg/day of beclomethasone dipropionate or equivalent) within the preceding 6 months (nasal & topical steroids allowed)
  • Received immunoglobulin or other blood product within 3 months prior to enrollment in this study
  • Subject has received an inactivated vaccine within 2 weeks or a live vaccine within 4 weeks prior to enrollment or plans to receive another vaccine within the next 28 days
  • Subject has an acute or chronic medical condition that, in the opinion of the investigator, would render vaccination unsafe or would interfere with the evaluation of responses. Those conditions include chronic conditions recognized as risk factors for influenza complications or as contraindicated for live vaccination, including chronic cardiac (exclusive of hypertension) or pulmonary conditions (including asthma), diabetes mellitus, or renal impairment
  • Subject has an acute illness or an oral temperature greater then 99.9 F(37.7 C)within 3 days of enrollment or vaccination. Subject who has acute illness that was treated, symptoms resolved are eligible to enroll as long as treatment is complete & symptoms resolved > 3 days prior to enrollment.
  • Subject is currently participating or plans to participate in a study that involves an experimental agent (vaccine, drug, biologic, device, blood product, or medication) or has received an experimental agent within 1 month of enrollment in this study, or intends to donate blood during this period.
  • Subject has any condition that would, in the opinion of the investigator, place the subject at an unacceptable risk of injury or render the subject unable to meet the requirements of the protocol
  • Subject has a diagnosis of schizophrenia, bi-polar disease, or other severe (disabling) chronic psychiatric diagnosis, or are receiving psychiatric drugs. Subjects who are receiving a single anti-depressant drug & are stable for at least 3 months prior to enrollment without decompensation are allowed enrollment into the study.
  • Subject has a history of alcohol or drug abuse in the 5 years of enrollment.
  • Subject has known human immunodeficiency virus, hepatitis B, or hepatitis C infection.
  • Subject has a previous history of Guillain-Barre syndrome within 6 weeks of receipt of influenza vaccine
  • Subject has any condition that the principal investigator (PI) believes may interfere with the successful completion of the study
Sexes Eligible for Study: All
18 Years and older   (Adult, Older Adult)
Yes
Contact information is only displayed when the study is recruiting subjects
United States
 
 
NCT01023711
URMC 09-005
No
Not Provided
Not Provided
John Treanor, University of Rochester
University of Rochester
Not Provided
Principal Investigator: John J. Treanor, M.D. University of Rochester
University of Rochester
April 2015

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP